Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low - Time to Sell?

Key Points

• Telix Pharmaceuticals stock reached a new 52-week low of $11.12, indicating a significant decline from its previous close of $11.34.
• Several brokerages have issued positive ratings for TLX, with HC Wainwright setting a price target of $23.00 and Wedbush recommending a target price of $22.00.
• Institutional investors are increasingly acquiring shares in Telix Pharmaceuticals, with multiple firms, including Pier Capital LLC and ABC Arbitrage SA, making new investments this year.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s stock price reached a new 52-week low on Monday . The company traded as low as $11.12 and last traded at $11.20, with a volume of 2252 shares. The stock had previously closed at $11.34.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TLX. HC Wainwright began coverage on shares of Telix Pharmaceuticals in a research note on Thursday, July 3rd. They set a "buy" rating and a $23.00 price target on the stock. Wedbush reaffirmed an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, June 12th. Finally, William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th.

Telix Pharmaceuticals Stock Down 3.4%

The business's 50-day simple moving average is $15.59 and its two-hundred day simple moving average is $16.74. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several institutional investors have recently made changes to their positions in TLX. Private Advisor Group LLC acquired a new position in shares of Telix Pharmaceuticals during the first quarter valued at $170,000. ABC Arbitrage SA bought a new stake in shares of Telix Pharmaceuticals in the first quarter worth about $451,000. Pier Capital LLC acquired a new position in shares of Telix Pharmaceuticals during the second quarter worth about $3,037,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Telix Pharmaceuticals during the second quarter worth approximately $297,000. Finally, Blair William & Co. IL bought a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at $217,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.